Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit

by Zacks Equity Research

QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.

3 Reasons Growth Investors Will Love ResMed (RMD)

by Zacks Equity Research

ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay

by Zacks Equity Research

The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.

BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase

by Zacks Equity Research

BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.

Charles River (CRL) Launches Viral Vector Tech Transfer Program

by Zacks Equity Research

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.

Here's Why ResMed (RMD) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

QIAGEN (QGEN) Develops Test for Research and CDx Application

by Zacks Equity Research

QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.

Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success

by Zacks Equity Research

Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.

Reasons to Hold Charles River (CRL) in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant

by Zacks Equity Research

Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

by Zacks Equity Research

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.

Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?

by Zacks Equity Research

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

by Zacks Equity Research

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Here's Why Investors Should Retain ICON (ICLR) Stock Now

by Zacks Equity Research

Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

Zacks.com featured highlights include Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp

by Zacks Equity Research

Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp are part of the Zacks Screen of the Week article.

ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.

Stereotaxis (STXS) Gets CE Recertification for Approved Products

by Zacks Equity Research

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.

Charles River (CRL) Banks on RMS Growth Amid Competition

by Zacks Equity Research

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Here's Why You Should Retain Edward Lifesciences (EW) for Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.

Scoop up These 4 GARP Stocks to Receive Handsome Returns

by Zacks Equity Research

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, RMD, BAH and BAP are some stocks that hold promise.

Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial

by Zacks Equity Research

Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.

Reasons to Include Alcon (ALC) in Your Portfolio Right Now

by Zacks Equity Research

New product launches and strong solvency bode well for Alcon (ALC).